CenterBook Partners LP Reduces Stock Position in Johnson & Johnson $JNJ

CenterBook Partners LP lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 87.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,126 shares of the company’s stock after selling 71,021 shares during the period. CenterBook Partners LP’s holdings in Johnson & Johnson were worth $1,878,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares in the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $4,877,174,000. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 3.5% in the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after buying an additional 835,146 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after buying an additional 52,074 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JNJ shares. Leerink Partners raised their target price on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Guggenheim upped their price objective on shares of Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Price Performance

Shares of JNJ opened at $246.90 on Friday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $246.96. The company has a market capitalization of $595.00 billion, a P/E ratio of 22.34, a price-to-earnings-growth ratio of 2.38 and a beta of 0.35. The firm has a 50 day moving average of $220.45 and a 200 day moving average of $198.55. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion for the quarter. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong clinical data: Phase 1b/2 OrigAMI‑4 showed a 56% overall response rate (10% complete responses) for subcutaneous amivantamab (RYBREVANT FASPRO) plus immunotherapy in first‑line recurrent/metastatic head & neck cancer — data that can materially broaden commercial and label potential if confirmed. Read More.
• Positive Sentiment: Regulatory acceleration: FDA granted Breakthrough Therapy Designation for subcutaneous amivantamab in advanced head & neck cancer — could shorten development timelines and improve commercial outlook. Read More.
• Positive Sentiment: Factory investment: J&J announced >$1 billion to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania — supports scaling of cell/biologics supply and signals continued capex to back pipeline commercialization. Read More.
• Positive Sentiment: Shareholder returns & analyst momentum: JNJ raised its quarterly payout (supports dividend investor base) and analysts have been raising targets/ratings, underpinning bullish sentiment. Read More.
• Neutral Sentiment: Strategic sale being explored: Bloomberg/Reuters report J&J is preparing a potential sale (~$20B) of its orthopedics unit; could unlock value but is early and dependent on deal terms/market appetite. Read More.
• Neutral Sentiment: Options & market attention: Elevated options activity and analyst write‑ups are amplifying near‑term moves but don’t change fundamentals. Monitor for concentrated directional trades. Read More.
• Negative Sentiment: Insider selling: Two executive vice presidents disclosed sizable share sales (combined filings) last week — a near‑term negative signal for some investors, though not proof of change in fundamentals. Read More.
• Negative Sentiment: Legal overhang: Coverage highlighting rising talc litigation risk continues to weigh on valuation and can cap multiple expansion despite operational gains. Read More.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.